Paper
0
Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
Authors
Journal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.